Objective: To determine the accuracy and precision of transcutaneous bilirubin (TcB) measurements in preterm neonates.
Introduction
Transcutaneous bilirubinometry has been shown to correlate with total serum bilirubin (TSB), and evidence indicates that TcB can be used as a reliable alternative to direct measurement of TSB. Furthermore, the use of transcutaneous bilirubin (TcB) values is more convenient and is less invasive than determination of TSB. 1 The majority of earlier studies have examined the use of TcB in term and near-term neonates, [2] [3] [4] [5] [6] [7] whereas studies that have been carried out in preterm neonates have yielded varying results. [8] [9] [10] [11] [12] [13] [14] [15] [16] Yasuda et al. 17 reported that the correlation between TcB and TSB was similar in both preterm and term neonates. However, Namba and Kitajima 18 reported that accuracy and reliability of TcB versus TSB were diminished in neonates with birth weights <1000 g or gestational ages <28 weeks, compared with results in larger, more mature preterm neonates. Approximately 50% of the earlier studies of TcB in preterm neonates have included extremely low birth weight neonates, although the exact number of these neonates is sometimes not specified; only one 16 has assessed interobserver precision. Jaundice is potentially more problematic in preterm neonates, and these neonates have risk factors that predispose to neurotoxicity at lower bilirubin levels. Although blood may be sampled routinely from ill preterm neonates, an accurate and precise noninvasive method of monitoring of jaundice in such neonates would be desirable if easily carried out between blood sampling times. In addition, some preterm neonates are relatively stable, and blood sampling may occur less frequently in this group. The use of point-of-care TcB monitoring in preterm neonates might enhance early detection of hyperbilirubinemia in this vulnerable population.
The objective of this study was to ascertain the accuracy of TcB versus TSB values, and to assess the precision of sequential TcB determinations in preterm neonates p34 weeks gestation.
Methods
This study was conducted in the Parkland Memorial Hospital (PMH) Neonatal Intensive Care Unit (NICU). The NICU population is predominantly Hispanic, and >95% of neonates admitted to the NICU are enrolled in the State of Texas Medicaid program. Approximately 97% of pregnant women who deliver at PMH attend a comprehensive system of prenatal clinics; the median number of prenatal visits for these women is 9, and approximately 75% are seen by 20 weeks gestation.
Preterm neonates p34 weeks gestation were studied prospectively from June 2007 to June 2008. Gestational age was determined by the best obstetric estimate on the basis of last menstrual period and prenatal sonographic evaluation. If the pediatric estimate 19 differed by >2 weeks, this value was used to assign gestational age. Neonates were stratified into three groups, depending on the gestational age assignment: 24 to 28 weeks (Group 1), 29 to 31 weeks (Group 2) and 32 to 34 weeks (Group 3). Neonates were eligible for this study if a TSB was ordered as part of their routine management. Neonates were excluded if they were diagnosed with hydrops fetalis or severe hemolytic disease were receiving or had received phototherapy or a double-volume exchange transfusion or were considered to be non-viable.
A study encounter was initiated when a TSB measurement was ordered as part of clinical management. TcB measurements were carried out within 45 min of blood sampling for TSB by one or two observers. The group of observers was composed of two of the authors (ETS and CAW) and 13 experienced neonatal nurse practitioners. Each neonate was limited to a maximum of two study encounters to minimize bias that could be introduced by a larger number of TcB versus TSB comparisons within an individual patient. When two TSB values were available, they were identified as TSB 1 and TSB 2 .
Transcutaneous bilirubin was determined using the JM-103 transcutaneous bilirubinometer (Draeger Air-Shields, Telford, PA, USA). 3 This device was used according to the manufacturer's recommendations, and daily quality control measures were performed. TcB was measured over the sternum, and included a single determination (S1) and a device-calculated mean of five determinations (S5); values shown in Results are for S1 (results for S5 are available on request). If results from two observers were available, only the TcB value obtained by observer 1 was utilized in the analysis of agreement between TcB and TSB. TSB determinations were performed in the clinical chemistry laboratory at PMH. This laboratory performs approximately 5000 total bilirubin assessments per month and utilizes the diazo JendrassikGrof with blank method (Olympus AU640, Olympus America Inc., Melville, NY, USA).
Data analyses included Kruskal-Wallis one-way ANOVA, w 2 -or Fisher's exact tests, Bland-Altman plot and predictive indices using target TSB values of >6, >8 and >10 mg per 100 ml. Linear regression was carried out with the absolute difference between TcB and TSB 1 values as the dependent variable, and the following as independent continuous variables: birth weight, gestational age, Apgar score at 1 min, Apgar score at 5 min, umbilical artery pH and postnatal age at TSB 1 . w 2 analysis was used to assess the relationships between absolute differences between TcB and TSB 1 and the categorical variables, such as route of delivery, gender, ethnicity and need for ventilatory support. The percentage of blood tests that potentially could be avoided was calculated as true negatives plus false negatives, divided by the total number of comparisons and multiplied by 100. In this analysis, the assumption is made that a TcB result below a specified cutoff value would identify a neonate who did not warrant a blood test. Variation between observers was assessed by intraclass correlation and method error (ME) with its associated coefficient of variation. The latter values were calculated using the following equations: ME ¼ (s.d. of the mean difference between observers)/(square root of 2), and coefficient of variation of the ME (CV ME ) ¼ [2ME/ (X 1 þ X 2 )]*100, where X 1 and X 2 are TcB mean values for observers 1 and 2, respectively. 20 Written informed consent was obtained from the parents or guardians of all study neonates. The Institutional Review Board of the University of Texas Southwestern Medical Center approved this study.
Results
Of 1143 admissions to the NICU during the study period, 528 neonates were p34 weeks. Of the 109 neonates for whom consent was obtained, 90 fulfilled the study criteria and had complete data collection. Demographic information regarding the three groups is shown in Table 1 . Comparisons between TcB and TSB 2 were made for 9, 14 and 18 neonates in Groups 1, 2 and 3, respectively.
The r-values for TcB versus TSB 1 in Groups 1, 2 and 3 were 0.92, 0.90 and 0.79, respectively. The r-values for TcB versus both TSB 1 and TSB 2 in Groups 1 (n ¼ 39), 2 (n ¼ 43) and 3 (n ¼ 49) were 0.90, 0.91 and 0.82, respectively. The data are combined in Figure 1 and shown as a scatterplot (r ¼ 0.88, P<0.001). The Bland-Altman plot (Figure 2 ), includes both TSB 1 and TSB 2 , and shows that the majority of the differences between TSB and TcB were within ± 2 mg per 100 ml; greater deviation between TcB and TSB was noted for some of the comparisons in each of the three groups. The mean and s.d. for TcBÀTSB in Groups 1, 2 and 3 were À1.1 ± 1.9, À0.8 ± 1.3 and À1.0 ± 1.6 mg per 100 ml, respectively. The plot illustrates the tendency for TcB to underestimate the TSB in the majority of comparisons. Regression lines drawn through the Bland-Altman data points for each group show that this tendency decreases with increasing bilirubin values, particularly in Groups 1 and 2 (r ¼ 0.79 and 0.49, respectively; both P<0.001). This trend was not significant in Group 3 (r ¼ 0.17, P>0.1).
There was no significant relationship between birth weight, gestational age, route of delivery, gender, ethnicity, Apgar score at 5 min, umbilical artery pH, need for ventilatory support or postnatal age at TSB 1 and the absolute differences between TcB and TSB 1 values. The only variable that was statistically significant was Apgar score at 1 min (r ¼ 0.20, P ¼ 0.02). There was no consistent pattern between the magnitude of the absolute differences (TSB 1 ÀTcB versus TSB 2 ÀTcB; P ¼ 0.74) for those neonates who had repeat TSB determinations. Table 2 describes the ability of TcB values >4, >6, and >8 mg per 100 ml to predict a TSB of >6, >8 and >10 mg per 100 ml, respectively. The majority of values for sensitivity, specificity, and negative predictive value were >0.70, and 7/9 (78%) of the sensitivity values were >0.90. Estimates of TSB determinations that could be avoided were 6 to 77%, and more TSB determinations in Group 1 (versus Groups 2 and 3) could be avoided at each TcB cutoff value.
Agreement between observers is shown in Table 3 . The difference between mean values for TcB determined by observers 1 and 2 ranged from 0.0 to 0.4 mg per 100 ml. Intraclass correlation ranged from 0.87 to 0.92 (all P<0.001). Coefficient of variation of the ME ranged from 6 to 20%, and values decreased from Group 1 to 3.
Discussion
The development of devices that measure TcB has resulted in a decreased need for serum bilirubin determinations, 17 found similar results in neonates with gestational age 27 to 36 weeks versus those with gestational age 37 to 41 weeks; this study included only one infant with gestational age <28 weeks. Namba and Kitajima 18 also studied the JM-103, but concluded that agreement between TSB and TcB was decreased in neonates with birth weights <1000 g or gestational ages <28 weeks compared with results in larger and more mature neonates.
Ebbesen et al. 16 reported that the results with the BiliCheck (Respironics, Inc., Murrysville, PA) TcB device were not greatly influenced by gestational age; these investigators concluded that this device is acceptable for screening both NICU and healthy infants with gestational ages X32 weeks. DeLuca et al.
14 also Transcutaneous bilirubinometry in preterm neonates ET Schmidt et al studied the BiliCheck in neonates with gestational ages 30 to 36 weeks; they concluded that reliability was good in this group, but less than the reliability observed in their nursery for healthy term infants. Knü pfer et al. 10 reported that use of the BiliCheck gave reliable results only for neonates with gestational ages >30 weeks. Maisels 1 concluded recently that both the BiliCheck and the JM-103 'are less reliable in predicting TSB in more preterm infants, particularly those younger than 30 weeks' gestation'.
We found that agreement between TcB and TSB was comparable among the three gestational age stratifications included in the study design. As in an earlier study using the JM-103 in our institution, there was a tendency for the TcB result to underestimate the corresponding TSB value. 2 In the current study, particularly in Groups 1 and 2, the regression lines drawn through individual group Bland-Altman data points indicated a tendency for the underestimation to be less at higher bilirubin values. In light of this trend, the clinician may be reassured as therapeutic intervention is, of course, more likely to be initiated at higher TSB values. Analyses of the predictive values of TcB >4, >6 or >8 mg per 100 ml showed that results were comparable among the gestational age-stratified groups, and neither gestational age nor birth weight was predictive of the magnitude of the difference Transcutaneous bilirubinometry in preterm neonates ET Schmidt et al between TcB and TSB. It should be noted that in those neonates with two TcB/TSB comparisons, we did not find that the difference noted on the first comparison was predictive of the difference on the second comparison. Overall, our results are similar to those of a large study evaluating the JM-103 in neonates X35 weeks, 3 and similar to or better than our experience using the JM-103 in larger, more mature neonates. 2 We found excellent precision between TcB results obtained by two independent observers. Means and s.d. were similar, and intraclass correlation values were all highly significant. Analysis of coefficients of variation of the ME 20 indicated that, as maturity of the neonates increased, the variation decreased. This finding is difficult to interpret in light of the other precision assessments and our overall results indicating comparable agreement among all groups. However, technical limitations in consistent placement of the probe on a very small neonate's chest may have contributed to this observation.
Although not detailed in this report, we did analyze differences between a single TcB determination (S1) and a device-calculated mean of five determinations (S5) using the JM-103 (data available upon request). There was no clear preference for either S1 or S5, and it appears that both methods are acceptable. As an S1 determination is more rapid, it is presumably favored in the majority of clinical circumstances.
This study has several limitations. We did not address the implications of developmentally regulated skin thickness on physical properties of light transmission in preterm compared with term neonates. The most immature neonates were studied at an earlier time period, and thus our data may not be applicable to chronologically older preterm neonates at a time when skin thickening occurs. By studying these neonates at an earlier time, TSB values were generally lower, especially in Group 1. Although the more immature neonates required a higher level of intensive care (Table 1) , we did not stratify for severity of illness or poor peripheral perfusion 8 within groups. We also did not assess the relation of TcB values to the initiation of phototherapy, as this was beyond the scope of our study.
Although not a limitation, we initially attempted both forehead and sternum measurements, but subsequently discontinued forehead measurements due to clinical concern regarding the pressure applied with the device. We suggest that care should be taken when obtaining TcB measurements at any site in the very immature neonate.
One might argue that preterm neonates would not benefit from TcB testing, as they are more likely to undergo frequent blood testing and to receive closer observation than more mature neonates. However, our results indicate that this technique has the potential to reduce blood sampling, 23 and therefore a painful procedure. 24 In addition, early and frequent assessment of TcB may prompt an earlier TSB determination to confirm an elevated TcB value; this may result in timely institution of therapeutic interventions to control hyperbilirubinemia. This study shows acceptable interobserver precision and good agreement between TcB and TSB, suggesting that point-of-care TcB determinations have an important role in assessing the preterm neonate for hyperbilirubinemia.
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